REG - Sareum Holdings PLC - Award of Share Options

Sareum HoldingsAnnouncement

16/12/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241216:nRSP1289Qa&default-theme=true

RNS Number : 1289Q  Sareum Holdings PLC  16 December 2024

Sareum Holdings PLC

 

("Sareum" or the "Company")

 

Award of Share Options

Transfer of Shares

Exercise of Warrants

Issue of Adviser Fee Shares

 

Cambridge, UK, 16 December 2024 - Sareum Holdings plc (AIM: SAR), a
biotechnology company developing next generation kinase inhibitors for
autoimmune disease and cancer, announces the grant of options to Tim Mitchell
(Chief Operating Officer), John Reader (Founder and Chief Scientific Officer)
and Stephen Parker (Executive Chairman)  over, in aggregate, 4,400,000
ordinary shares of 1.25 pence each in the capital of the Company ("Ordinary
Shares") (the "Options"). A total of 890,000 Options will be granted under the
Company's Enterprise Management Incentive ("EMI") plan, and the remaining
Options will be granted under an unapproved share option scheme on identical
terms to the EMI options, as further detailed below.

 

The Options have an exercise price of 30.48 pence, being equal to a premium of
15.0% to the closing mid-market price of an Ordinary Share on 13 December
2024, being the last trading day before the award of the Options. The Options
will be structured to vest from 16 December 2027 and will lapse on the fifth
anniversary of the date of grant. Details of the individual tranches are as
follow:

 

·    Tranche 1: 50% of the Options will vest on 16 December 2027

·    Tranche 2: 50% of the Options will vest on 16 December 2027 providing
the Company has met certain commercial and technical milestones

 

Details of the Options award is detailed in the table below:

 

 Director / PDMR                     Current options held  New EMI options awarded  New unapproved options awarded  Total options held
 Tim Mitchell, Founder & COO         1,211,434             445,000                  755,000                         2,411,434
 John Reader, Founder & CSO          1,211,434             445,000                  1,555,000                       3,211,434
 Stephen Parker, Executive Chairman  492,908               -                        1,200,000                       1,692,908

 

Following the grant of the new Options, a total of 7,430,058 options are
outstanding, representing approximately 6.0% of the Company's issued share
capital following Admission.

 

Transfer of Shares

 

The Company also announces that Dr. Tim Mitchell, has transferred 451,960 of
his Ordinary Shares to his spouse, resulting in both Dr Mitchell and his
spouse holding 651,960 Ordinary Shares, representing, in aggregate,
approximately 1.04% of the Company's issued share capital following Admission.

 

Exercise of Warrants

 

The Company announces that it has received an exercise of warrants notice to
subscribe for a total of 159,091 new Ordinary Shares at a price of 22.5 pence
per new Ordinary Share for a total consideration to the Company of
£35,795.48.

 

Issue of Adviser Fee Shares

 

Finally, the Company announces that it has issued 22,222 Ordinary Shares to an
adviser to settle amounts due in relation to advice provided.

 

Admission and Total Voting Rights

 

The Company has applied for 181,313 new Ordinary Shares to be to be admitted
to trading on AIM ("Admission") by 8.00 a.m. on or around 20 December 2024.

 

The new Ordinary Shares will, when issued, be credited as fully paid and will
rank pari passu in all respects with the existing Ordinary Shares of the
Company including the right to receive all dividends or other distributions
made, paid or declared in respect of such shares after Admission.

 

Following Admission, the total number of Ordinary Shares in issue will be
124,927,651 and the total number of voting rights will thereafter be
124,927,651 and this figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

For further information, please contact:

 Sareum Holdings plc

 Stephen Parker, Executive Chairman               01223 497700

                                                  ir@sareum.co.uk
 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                      020 7409 3494

 Hybridan LLP (Corporate Broker)

 Claire Noyce                                     020 3764 2341

 ICR Healthcare (Financial PR)

 Jessica Hodgson / Davide Salvi / Kumail Waljee   020 3709 5700

 

About Sareum

 

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase
inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, including
psoriasis, and has completed Phase 1 clinical development.

 

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

 

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(about:blank) .

 

PDMR Notification Form:

The below form is disclosed in accordance with the requirements of the EU's
Market Abuse Regulation and in relation to certain dealings by directors
pursuant to the Director Subscription and issue of Salary Conversion Shares:

 

 1.   Details of the person discharging managerial responsibilities/person closely
      associated
 a)   Name:                                                         Tim Mitchell
 2.   Reason for the notification
 a)   Position/status:                                              PDMR - Founder & COO
 b)   Initial notification/Amendment:                               Initial notification
 3.   Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name:                                                         Sareum Holdings plc
 b)   LEI:                                                          213800PKERN2DY8FFM72
 4.   Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument:  Options over ordinary shares of 0.0125 pence each in the share capital of

                                                             Sareum Holdings plc
      Identification code:

                                                                    GB00B02RFS12
 b)   Nature of the transaction:                                    Issue of options
 c)   Price(s) and volume(s):                                       Price(s)  Volume(s)

                                                             30.48p    1,200,000

 d)   Aggregated information:

      ·    Aggregated volume:                                       Single transaction as in 4c) above

      ·    Price:
 e)   Date of the transaction:                                      16 December 2024
 f)   Place of the transaction:                                     Outside a trading venue

d)

Aggregated information:

·    Aggregated volume:

·    Price:

 

Single transaction as in 4c) above

 

e)

Date of the transaction:

16 December 2024

f)

Place of the transaction:

Outside a trading venue

 

 

 

 1.   Details of the person discharging managerial responsibilities/person closely
      associated
 a)   Name:                                                         John Reader
 2.   Reason for the notification
 a)   Position/status:                                              Director - Founder & CSO
 b)   Initial notification/Amendment:                               Initial notification
 3.   Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name:                                                         Sareum Holdings plc
 b)   LEI:                                                          213800PKERN2DY8FFM72
 4.   Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument:  Options over ordinary shares of 0.0125 pence each in the share capital of

                                                             Sareum Holdings plc
      Identification code:

                                                                    GB00B02RFS12
 b)   Nature of the transaction:                                    Issue of options
 c)   Price(s) and volume(s):                                       Price(s)  Volume(s)

                                                             30.48p    2,000,000

 d)   Aggregated information:

      ·    Aggregated volume:                                       Single transaction as in 4c) above

      ·    Price:
 e)   Date of the transaction:                                      16 December 2024
 f)   Place of the transaction:                                     Outside a trading venue

d)

Aggregated information:

·    Aggregated volume:

·    Price:

 

Single transaction as in 4c) above

 

e)

Date of the transaction:

16 December 2024

f)

Place of the transaction:

Outside a trading venue

 

 

 

 1.   Details of the person discharging managerial responsibilities/person closely
      associated
 a)   Name:                                                         Stephen Parker
 2.   Reason for the notification
 a)   Position/status:                                              Director - Executive Chairman
 b)   Initial notification/Amendment:                               Initial notification
 3.   Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name:                                                         Sareum Holdings plc
 b)   LEI:                                                          213800PKERN2DY8FFM72
 4.   Details of the transaction(s): section to be repeated for (i) each type of
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument:  Options over ordinary shares of 0.0125 pence each in the share capital of

                                                             Sareum Holdings plc
      Identification code:

                                                                    GB00B02RFS12
 b)   Nature of the transaction:                                    Issue of options
 c)   Price(s) and volume(s):                                       Price(s)  Volume(s)

                                                             30.48p    1,200,000

 d)   Aggregated information:

      ·    Aggregated volume:                                       Single transaction as in 4c) above

      ·    Price:
 e)   Date of the transaction:                                      16 December 2024
 f)   Place of the transaction:                                     Outside a trading venue

d)

Aggregated information:

·    Aggregated volume:

·    Price:

 

Single transaction as in 4c) above

 

e)

Date of the transaction:

16 December 2024

f)

Place of the transaction:

Outside a trading venue

 

 

END

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUVOVRSKUUAAA